Tag: COM701
-
Compugen Reports Strong Third Quarter 2025 Results Highlighting COM701 Data and MAIA-Ovarian Trial Progress
Overview of Q3 2025 Results Compugen has released its third quarter 2025 results, alongside key data updates from the company’s oncology pipeline. The highlights focus on COM701, Company-backed clinical data presented at ESMO 2025, and the ongoing progress of the MAIA-ovarian platform trial. The quarterly update underscores Compugen’s strategic emphasis on translating scientific insights into…
-
Compugen Q3 2025 Results: COM701 Data at ESMO & MAIA-Ovarian
Overview of the Quarter Compugen released its third-quarter 2025 results, underscoring advances in its oncology program and the ongoing development of the COM701 program. The company highlighted Phase 1 data from COM701 that were presented at the ESMO 2025 conference, and provided updates on the MAIA-ovarian platform trial, which is designed to explore the potential…
-
Compugen Announces Q3 2025 Results Highlighting COM701 ESMO 2025 Data and MAIA-Ovarian Platform Trial Progress
Overview of Q3 2025 Results Compugen has released its third-quarter 2025 results, underscoring continued momentum in its oncology pipeline and the strategic progress of key clinical programs. The company reaffirmed its commitment to advancing targeted cancer therapies, with a particular focus on COM701 data presented at ESMO 2025 and the ongoing expansion of the MAIA-ovarian…